Cipla share price, financials and monitoring
Cipla sells pharmaceutical products across India and international markets. Product launches, geographic mix, regulatory disclosures and research spending shape the business.
Dates and sources
The last NSE bhavcopy close is dated 4 Nov 2026. Valuation observations are dated 4 Nov 2026. The latest financial quarter ends 30 Sept 2026. These are separate observation dates, not live quotes. Financial reporting basis: consolidated.
Read the Nifty drivers report · Understand index funds and ETFs · NSE daily reports
Year ended 2026-03-31 and the latest quarter
The tables use one reporting basis across the displayed history, preferring consolidated where sufficient history is available. Each row identifies its period and original filing. Profit is attributable to owners where disclosed; otherwise total profit is labelled.
Revenue history
A rising top line is evidence of scale, not proof of value creation. Read it with profit, capital efficiency, cash conversion and the business-specific guideposts above.
₹ crore values are presented as filed or normalized from company/exchange financial results. Banks and NBFCs use total income because interest is part of their operating business. Industrial companies use revenue where available.
Historical values can be restated. EPS retains the share basis in its original filing and may not be directly comparable across corporate actions. Gaps in annual periods remain gaps; the source and reporting basis are retained.
| Year ended | Revenue | PAT | Reported EPS | Basis | Evidence |
|---|---|---|---|---|---|
| Year ended 2022-03-3131 Mar 2022 | ₹21,763 cr | ₹2,517 cr | 31.2 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2023-03-3131 Mar 2023 | ₹22,753 cr | ₹2,802 cr | 34.72 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2024-03-3131 Mar 2024 | ₹25,774 cr | ₹4,122 cr | 51.05 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2025-03-3131 Mar 2025 | ₹27,548 cr | ₹5,273 cr | 65.29 | Consolidated · PAT: owners | Filing ↗ |
| Year ended 2026-03-3131 Mar 2026 | ₹28,163 cr | ₹3,879 cr | 48.03 | Consolidated · PAT: owners | Filing ↗ |
Eight reported quarters
Publication date is shown separately from the period end. A June quarter was not knowable on 30 June; it entered the public record only when the company filed it.
| Quarter ended | Revenue | PAT | Reported EPS | Published | Evidence |
|---|---|---|---|---|---|
| 30 Sept 2026Consolidated · PAT: owners | ₹7,404 cr | ₹878 cr | 10.86 | 27 Oct 2026 | Filing ↗ |
| 30 Jun 2026Consolidated · PAT: owners | ₹7,119 cr | ₹789 cr | 9.77 | 23 Jul 2026 | Filing ↗ |
| 31 Mar 2026Consolidated · PAT: owners | ₹6,541 cr | ₹555 cr | 6.87 | 13 May 2026 | Filing ↗ |
| 31 Dec 2025Consolidated · PAT: owners | ₹7,074 cr | ₹676 cr | 8.37 | 23 Jan 2026 | Filing ↗ |
| 30 Sept 2025Consolidated · PAT: owners | ₹7,589 cr | ₹1,351 cr | 16.73 | 30 Oct 2025 | Filing ↗ |
| 30 Jun 2025Consolidated · PAT: owners | ₹6,957 cr | ₹1,298 cr | 16.07 | 25 Jul 2025 | Filing ↗ |
| 31 Mar 2025Consolidated · PAT: owners | ₹6,730 cr | ₹1,222 cr | 15.13 | 13 May 2025 | Filing ↗ |
| 31 Dec 2024Consolidated · PAT: owners | ₹7,073 cr | ₹1,571 cr | 19.45 | 28 Jan 2025 | Filing ↗ |
Use the metric that fits the business.
ROCE is not shown for banks and NBFCs because deposits and borrowings are operating raw material rather than ordinary financing. Missing or inapplicable values remain unavailable.
Who owns the company?
Shareholding is shown from the latest available filing. Institutional subtotals depend on the filing taxonomy and are labelled by their source basis.
Profit is only one part of the evidence.
These are investigation prompts, not pass-or-fail verdicts. Business model, working-capital structure and reporting basis determine how each value should be interpreted.
Dated evidence, linked to its source.
The page shows selected annual and quarterly periods. The financial tables, market observations and ownership figures can have different dates.
Related company and methodology pages
Cipla FAQ
What does Cipla do?
Cipla sells pharmaceutical products across India and international markets. Product launches, geographic mix, regulatory disclosures and research spending shape the business.
What should investors monitor for Cipla?
Important operating evidence includes india and overseas mix, product launches, regulatory disclosures, research spending. These are research guideposts, not automatic trading signals.
Are the Cipla financials consolidated or standalone?
Altys prefers consolidated financials when available and labels the reporting basis in each table. The latest annual row on this page is consolidated.
Does Altys recommend buying or selling Cipla?
No. Altys provides sourced financial data, research context and monitoring infrastructure. It does not issue a buy, sell or hold recommendation on this page.
Research Cipla once. Keep watching what changes.
Altys can connect new results, filings, concalls, guidance, ownership and company-specific KPIs with the investment team’s original thesis and portfolio context.